Acne as a chronic systemic disease

Clinics in Dermatology

Volumn 32, Issue 3, 2014, Pages 389-396

  Zouboulis, Christos C ^a  

^a DESSAU MEDICAL CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANDROGEN; ARACHIDONIC ACID; CONTRACEPTIVE AGENT; CORTICOTROPIN; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GLUCOCORTICOID; GONADOTROPIN; HYDROCORTISONE; INSULIN; ISOTRETINOIN; LEUKOTRIENE B4; LINOLEIC ACID; METFORMIN; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID 21 MONOOXYGENASE; TESTOSTERONE; FAT INTAKE;

ACANTHOSIS NIGRICANS; ACNE; ACNE VULGARIS; ACROCEPHALOSYNDACTYLY; ADRENAL GLAND; CONGENITAL ADRENAL HYPERPLASIA; DISEASE ASSOCIATION; FGFR2 GENE; GONADOTROPIN RELEASE; HIRSUTISM; HUMAN; HYPERANDROGENISM; INFERTILITY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOGENESIS; LOW DRUG DOSE; MALE TYPE ALOPECIA; NOTE; OVARY POLYCYSTIC DISEASE; PAPA SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; SAPHO SYNDROME; SEBACEOUS GLAND; SEBORRHEA; STEROIDOGENESIS; TREATMENT RESPONSE; ALOPECIA; COMPLICATION; DERMATITIS, SEBORRHEIC; FAT INTAKE; FEMALE; GENETICS; INFLAMMATION; SYNDROME;

ACANTHOSIS NIGRICANS; ACNE VULGARIS; ACQUIRED HYPEROSTOSIS SYNDROME; ACROCEPHALOSYNDACTYLIA; ADRENAL HYPERPLASIA, CONGENITAL; ALOPECIA; DERMATITIS, SEBORRHEIC; DIETARY FATS; FEMALE; HIRSUTISM; HUMANS; HYPERANDROGENISM; INFLAMMATION; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; SYNDROME;

EID: 84899115695     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2013.11.005     Document Type: Note

References (81)

1. Gollnick H.P., Finlay A.Y., Shear N. Can we define acne as a chronic disease? If so, how and when?. Am J Clin Dermatol 2008, 9:279-284.
2. Zouboulis C.C. Is acne vulgaris a genuine inflammatory disease?. Dermatology 2001, 203:277-279.
3. Zouboulis C.C. Acne and sebaceous gland function. Clin Dermatol 2004, 22:360-366.
4. Zouboulis C.C., Eady A., Philpott M., et al. What is the pathogenesis of acne?. Exp Dermatol 2005, 14:143-152.
5. Kurokawa I., Danby F.W., Ju Q., et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009, 18:821-832.
6. Zouboulis C.C. Propionibacterium acnes and sebaceous lipogenesis: a love-hate relationship?. J Invest Dermatol 2009, 129:2093-2096.
7. Frost P., Gomez E.C. Inhibitors of sex hormones: development of experimental models. Adv Biol Skin 1972, 12:403-420.
8. Guy R., Ridden C., Barth J., et al. Isolation and maintenance of the human pilosebaceous duct: 13-cis retinoic acid acts directly on the duct in vitro. Br J Dermatol 1993, 128:242-248.
9. Guy R., Ridden C., Kealey T. The improved organ maintenance of the human sebaceous gland: modeling in vitro the effects of epidermal growth factor, androgens, estrogens, 13-cis retinoic acid, and phenol red. J Invest Dermatol 1996, 106:454-460.
10. Zouboulis C.C., Xia L., Akamatsu H., et al. The human sebocyte culture model provides new insights into development and management of seborrhea and acne. Dermatology 1998, 196:21-31.
11. Mirshahpanah P., Maibach H.I. Models in acnegenesis. Cutan Ocul Toxicol 2007, 26:195-202.
12. Nakatsuji T., Liu Y.T., Huang C.P., et al. Antibodies elicited by inactivated propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris. J Invest Dermatol 2008, 128:2451-2457.
13. Xia L.Q., Zouboulis C., Detmar M., et al. Isolation of human sebaceous glands and cultivation of sebaceous gland-derived cells as an in vitro model. J Invest Dermatol 1989, 93:315-321.
14. Zouboulis C.C., Schagen S., Alestas T. The sebocyte culture: A model to study the pathophysiology of the sebaceous gland in sebostasis, seborrhea and acne. Arch Dermatol Res 2008, 300:397-413.
15. Zouboulis C.C., Seltmann H., Neitzel H., et al. Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). J Invest Dermatol 1999, 113:1011-1020.
16. Centers for Disease Control. "Classifications of diseases and functioning and disability". In: Classifications of Diseases and Functioning and Disability. Definition of Disability Reference. National Center for Health Statistics; 2001.
17. O'Halloran J., Miller G.C., Britt H. Defining chronic conditions for primary care with ICPC-2. Fam Pract 2004, 21:381-386.
18. Cunliffe W.J. Acne and unemployment. Br J Dermatol 1986, 115:386.
19. Goulden V., McGeown C.H., Cunliffe W.J. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol 1999, 141:297-300.
20. James W.D. Clinical practice. Acne. N Engl J Med 2005, 352:1463-1472.
21. Kellett S.C., Gawkrodger D.J. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999, 140:273-282.
22. Niemeier V., Kupfer J., Demmelbauer-Ebner M., et al. Coping with acne vulgaris. Evaluation of the chronic skin disorder questionnaire in patients with acne. Dermatology 1998, 196:108-115.
23. Tan J. The Canadian acne epidemiologic survey: baseline demographics and interim analysis. J Am Acad Dermatol 2004, 50:15.
24. Thiboutot D.M., Lookingbill D.P. Acne: acute or chronic disease?. J Am Acad Dermatol 1995, 32(Suppl.):S2-S5.
25. Thiboutot D., Gollnick H., Bettoli V., et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009, 60:S1-S50.
26. Collier C.N., Harper J.C., Cafardi J.A., et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008, 58:56-59.
27. Dreno B., Layton A., Zouboulis C.C., et al. Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol 2013, 27:1063-1070.
28. Goulden V., Stables G.I., Cunliffe W.J. Prevalence of facial acne in adults. J Am Acad Dermatol 1999, 41:577-580.
29. Poli F., Dreno B., Verschoore M. An epidemiologic study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001, 15:541-545.
30. Chen W., Obermayer-Pietsch B., Hong J.-B., et al. Acne-associated syndromes: models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol 2011, 25:637-646.
31. Dessinioti C., Katsambas A. Congenital adrenal hyperplasia. Dermatoendocrinol 2009, 1:87-91.
32. Trakakis E., Basios G., Trompoukis P., et al. An update to 21-hydroxylase deficient congenital adrenal hyperplasia. Gynecol Endocrinol 2010, 26:63-71.
33. New M.I. An update of congenital adrenal hyperplasia. Ann N Y Acad Sci 2004, 1038:14-43.
34. Speiser P.W., White P.C. Congenital adrenal hyperplasia. N Engl J Med 2003, 349:776-788.
35. Witchel S.F. Nonclassic congenital adrenal hyperplasia. Steroids 2013, 78:747-750.
36. Caputo V., Fiorella S., Curiale S., et al. Refractory acne and 21-hydroxylase deficiency in a selected group of female patients. Dermatology 2010, 220:121-127.
37. Trakakis E., Rizos D., Loghis C., et al. The prevalence of non-classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Greek women with hirsutism and polycystic ovary syndrome. Endocr J 2008, 55:33-39.
38. Zouboulis C.C., Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003, 206:37-53.
39. Orfanos C.E. Antiandrógenos en dermatología. Arch Arg Derm 1982, 32(Suppl. 1):51-55.
40. Orfanos C.E., Adler Y.D., Zouboulis C.C. The SAHA syndrome. Horm Res 2000, 54:251-258.
41. Zouboulis C.C., Chen W.C., Thornton M.J., et al. Sexual hormones in human skin. Horm Metab Res 2007, 39:85-95.
42. Lowenstein E.J. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther 2006, 19:210-223.
43. Carmina E. Mild androgen phenotypes. Best Pract Res Clin Endocrinol Metab 2006, 20:207-220.
44. Chen W.C., Zouboulis C.C. Hormones and the pilosebaceous unit. Dermatoendocrinol 2009, 1:81-86.
45. Carmina E., Rosato F., Janni A., et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006, 91:2-6.
46. Zouboulis C.C., Rabe T. Hormonal antiandrogens in acne treatment. J Dtsch Dermatol. Ges 2010, 8(Suppl. 1):S60-S74.
47. Witchel S.F., Recabarren S.E., Gonzalez F., et al. Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine 2012, 42:526-534.
48. Ewens K.G., Stewart D.R., Ankener W., et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab 2010, 95:2306-2315.
49. Deligeoroglou E., Kouskouti C., Christopoulos P. The role of genes in the polycystic ovary syndrome: predisposition and mechanisms. Gynecol Endocrinol 2009, 25:603-609.
50. Wehr E., Schweighofer N., Moller R., et al. Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome. Metabolism 2010, 59:575-580.
51. Adler Y.D., Zouboulis C.C., Geilen C.C., et al. Eine seltene Variante des SAHA Syndroms. Z Hautkr 2000, 76:327-328.
52. Rager K.M., Omar H.A. Androgen excess disorders in women: the severe insulin-resistant hyperandrogenic syndrome, HAIR-AN. Sci World J 2006, 6:116-121.
53. Makrantonaki E., Vogel K., Fimmel S., et al. Interplay of IGF-I and 17beta-estradiol at age-specific levels in human sebocytes and fibroblasts in vitro. Exp Gerontol 2008, 43:939-946.
54. Blomberg M., Jeppesen E.M., Skovby F., et al. FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature. Dermatology 2010, 220:297-305.
55. Chamot A.M., Vion B., Gerster J.C. Acute pseudoseptic arthritis and palmoplantar pustulosis. Clin Rheumatol 1986, 5:118-123.
56. Hayem G., Bouchaud-Chabot A., Benali K., et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 1999, 29:159-171.
57. Kahn M.F., Khan M.A. The SAPHO syndrome. Baillieres Clin Rheumatol 1994, 8:333-362.
58. Kahn M.F., Bouvier M., Palazzo E., et al. Sternoclavicular pustulotic osteitis (SAPHO). 20-year interval between skin and bone lesions. J Rheumatol 1991, 18:1104-1108.
59. Hurtado-Nedelec M., Chollet-Martin S., Nicaise-Roland P., et al. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford) 2008, 47:1160-1167.
60. Olivieri I., Padula A., Palazzi C. Pharmacological management of SAPHO syndrome. Expert Opin Investig Drugs 2006, 15:1229-1233.
61. Lindor N.M., Arsenault T.M., Solomon H., et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 1997, 72:611-615.
62. Wise C.A., Gillum J.D., Seidman C.E., et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Molec Genet 2002, 11:961-969.
63. Kanazawa N., Furukawa F. Autoinflammatory syndromes with a dermatological perspective. J Dermatol 2007, 34:601-618.
64. Dierselhuis M.P., Frenkel J., Wulffraat N.M., et al. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 2005, 44:406-408.
65. Apert E. De la acrocéphalosyndactylie. Bull Soc Med Hop (Paris) 1906, 23:1310-1330.
66. Boulet S.L., Rasmussen S.A., Honein M.A. A population-based study of craniosynostosis in metropolitan Atlanta, 1989-2003. Am J Med Genet A 2008, 146A:984-991.
67. Solomon L.M., Fretzin D., Pruzansky S. Pilosebaceous abnormalities in Apert's syndrome. Arch Dermatol 1970, 102:381-385.
68. Melnik B.C., Schmitz G. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. Exp Dermatol 2009, 18:833-841.
69. Wilkie A.O., Slaney S.F., Oldridge M., et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 1995, 9:165-172.
70. Melnik B.C. Role of FGFR2-signaling in the pathogenesis of acne. Dermatoendocrinol 2009, 1:141-156.
71. Melnik B.C. FoxO1-the key for the pathogenesis and therapy of acne?. J Dtsch Dermatol Ges 2010, 8:105-114.
72. Melnik B.C. Is nuclear deficiency of FoxO1 due to increased growth factor/PI3K/Akt-signalling in acne vulgaris reversed by isotretinoin treatment?. Br J Dermatol 2010, 162:1398-1400.
73. Letawe C., Boone M., Pierard G.E. Digital image analysis of the effect of topically applied linoleic acid on acne microcomedones. Clin Exp Dermatol 1998, 23:56-58.
74. Alestas T., Ganceviciene R., Fimmel S., et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med (Berl) 2006, 84:75-87.
75. Wrobel A., Seltmann H., Fimmel S., et al. Differentiation and apoptosis in human immortalized sebocytes. J Invest Dermatol 2003, 120:175-181.
76. Zouboulis C.C., Nestoris S., Adler Y.D., et al. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol 2003, 139:668-670.
77. Steiner P.E. Necropsies on Okinawans; anatomic and pathologic observations. Arch Pathol (Chic) 1946, 42:359-380.
78. Simopoulos A.P. Evolutionary aspects of diet and essential fatty acids. World Rev Nutr Diet 2001, 88:18-27.
79. Cordain L., Lindeberg S., Hurtado M., et al. Acne vulgaris: a disease of Western civilization. Arch Dermatol 2002, 138:1584-1590.
80. Thiboutot D.M., Strauss J.S. Diet and acne revisited. Arch Dermatol 2002, 138:1591-1592.
81. Thielitz A., Reinhold D., Vetter R., et al. Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol 2007, 127:1042-1051.